Key terms
About PTCT
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PTCT news
Apr 09
5:40am ET
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)
Mar 28
8:34am ET
PTC Therapeutics submits MAA for sepiapterin in PKU to EMA
Mar 25
1:55pm ET
Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
Mar 25
4:55am ET
Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
Mar 21
11:28am ET
Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
Mar 19
11:05am ET
Buy Rating for PTC Therapeutics Bolstered by Positive Regulatory Prospects and Gene Therapy Advances
Mar 19
7:33am ET
PTC Therapeutics provides regulatory updates
Mar 08
7:26am ET
PTC Therapeutics (PTCT) Receives a Hold from RBC Capital
Mar 06
11:15pm ET
PTC Therapeutics: Navigating Challenges and Pursuing Growth Amidst Regulatory Hurdles
Mar 06
6:16am ET
Buy Rating Affirmed for PTC Therapeutics Amid Promising Regulatory Progress and Market Opportunity
Mar 01
10:17am ET
PTC Therapeutics price target raised to $28 from $22 at RBC Capital
Mar 01
7:26am ET
PTC Therapeutics (PTCT) Receives a Hold from RBC Capital
Mar 01
7:15am ET
Positive Outlook for PTC Therapeutics: A Comprehensive Buy Rating Justification
Mar 01
7:08am ET
PTC Therapeutics price target lowered to $30 from $32 at TD Cowen
Mar 01
6:27am ET
Downgrade to Sell: PTC Therapeutics Faces Significant Commercial and Competitive Challenges
Mar 01
5:50am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioLife Solutions (BLFS), Cooper Co (COO) and PTC Therapeutics (PTCT)
Mar 01
3:15am ET
PTC Therapeutics Sell Rating Reinforced Amidst Commercial Challenges and Regulatory Risks
Mar 01
2:55am ET
Barclays Keeps Their Hold Rating on PTC Therapeutics (PTCT)
Feb 29
10:45pm ET
PTC Therapeutics: Hold Rating Amidst Revenue Downturn and Regulatory Hurdles
Feb 29
4:36pm ET
PTC Therapeutics Q4 and Fiscal Year-End Financial Update Call
Feb 29
4:13pm ET
PTC Therapeutics sees FY24 revenue $600M-$680M, consensus $612.29M
Feb 29
4:12pm ET
PTC Therapeutics reports Q4 EPS ($2.06), consensus 50c
Feb 27
12:50pm ET
SHAREHOLDER ALERT: Potential Recovery for PTC Therapeutics, Inc. (PTCT) Investors
Feb 14
8:00am ET
PTC Therapeutics put buyer realizes 42% same-day gains
Feb 03
1:11pm ET
PTC Therapeutics price target lowered to $43 from $45 at JPMorgan
Jan 26
10:12am ET
PTC Therapeutics price target lowered to $22 from $27 at RBC Capital
Jan 26
6:56am ET
RBC Capital Keeps Their Hold Rating on PTC Therapeutics (PTCT)
Jan 26
4:31am ET
PTC Therapeutics Faces Negative EMA Opinion on Translarna Renewal
Jan 26
12:56am ET
Recommendation to Sell: PTC Therapeutics Faces Market Withdrawal and Increased Competition
Jan 25
6:45pm ET
William Blair Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
Jan 25
4:55pm ET
PTC Therapeutics falls 10% to $23.88 after CHMP negative opinion for Translarna
No recent press releases are available for PTCT
PTCT Financials
Key terms
Ad Feedback
PTCT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PTCT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
